Introduction to Quotient Bioresearch

Quotient Bioresearch stands as a premier contract research organization (CRO) headquartered in Farnborough, Hampshire, United Kingdom. With over three decades of industry leadership, the company has cemented its reputation as a trusted partner for pharmaceutical, biotechnology, and life sciences organizations worldwide. Specializing in bioanalysis, drug metabolism, and pharmacokinetics (DMPK), Quotient Bioresearch delivers high-quality data and regulatory support that accelerates drug development timelines. The firm’s state-of-the-art laboratories, accredited to ISO 17025 and GLP/GCP standards, ensure precision and compliance at every stage. As a top-tier Healthcare company, Quotient Bioresearch supports clients from early discovery through late-phase clinical trials, offering bespoke analytical methods and biomarker assays. The company’s market reputation is built on scientific excellence, reliability, and a client-centric approach that has fostered lasting partnerships with top 20 pharma firms and emerging biotechs alike. With a team of over 300 highly skilled scientists, the organization continues to push boundaries in ligand-binding assays, LC-MS/MS, and flow cytometry. The Quotient Bioresearch company profile reflects a deep commitment to advancing human health through rigorous science and innovative technologies.

Industry Focus and Global Reach

Quotient Bioresearch primarily serves the pharmaceutical and biotechnology sectors, with a strong foothold in the UK, Europe, and North America. The company’s expertise extends to oncology, central nervous system disorders, immunology, and infectious diseases. By integrating advanced automation and informatics, Quotient Bioresearch delivers rapid turnaround without compromising data integrity. Clients rely on the firm for critical decision-making, from IND filings to NDA submissions. The company’s role within the CRO industry is pivotal: it bridges the gap between preclinical research and clinical success, ensuring that promising compounds are thoroughly evaluated for safety and efficacy. Regulatory authorities such as the MHRA, FDA, and EMA routinely accept submissions supported by Quotient Bioresearch data, underscoring its global compliance standards.

Company History and Business Evolution

Founded in 1990 in the historic market town of Alconbury, Cambridgeshire, Quotient Bioresearch began as a small bioanalytical laboratory serving local pharmaceutical companies. The visionary founders recognized a growing need for specialized DMPK expertise that larger CROs often overlooked. Over the next decade, the company expanded its service portfolio, introducing ligand-binding assays and early ADME screening. A major milestone occurred in 2004 when the company moved to its current headquarters in Farnborough, investing in state-of-the-art mass spectrometry suites. The subsequent years saw strategic acquisitions: in 2011, Quotient Bioresearch acquired a leading biomarker assay developer, strengthening its immunochemistry capabilities. By 2015, the firm had opened a satellite office in the United States, spanning into the North American market. Another pivotal moment came in 2019 when the company launched its proprietary automated high-throughput analysis platform, cutting turnaround times by 40%. In 2022, Quotient Bioresearch entered a strategic partnership with a major biopharma firm to co-develop next-generation bioanalytical tools. Today, the company employs over 300 scientists across two continents and processes more than 50,000 samples annually. The business evolution from a small lab to a global CRO underscores its resilience and ability to anticipate market needs. Despite industry consolidation, Quotient Bioresearch has maintained its independence, focusing on deep scientific expertise rather than broad service commoditization. The company’s growth trajectory continues with investments in AI-driven data analysis and expanded regulatory consultancy services.

Quotient Bioresearch at a Glance

• Headquarters: Farnborough, Hampshire, UK
• Founded: 1990
• CEO: Dr. John Harrison (current)
• Revenue: £45 million (estimated 2023)
• Employees: 300+
• Accreditations: ISO 17025, GLP, GCP, CLIA
• Service Areas: Bioanalysis, DMPK, Biomarker Assays, ADME, Toxicokinetics
• Technologies: LC-MS/MS, Ligand-Binding Assays (ELISA, MSD), Flow Cytometry, qPCR
• Key Clients: Top 20 pharmaceutical companies, mid-size biotechs, academic research centers
• Regulatory Submissions: Support for INDs, NDAs, BLAs worldwide
• Therapeutic Focus: Oncology, CNS, Immunology, Infectious Diseases, Metabolic Disorders
• Global Presence: UK (HQ), USA (Boston office)
• Number of lab facilities: 3 (2 in UK, 1 in US)
• Annual sample throughput: >50,000
• Quality systems: Fully validated LIMS, 21 CFR Part 11 compliant
• Partnerships: Collaborations with Quotient Sciences, leading pharma consortia
• Industry recognition: Named “Top CRO to Work For” by PharmaTimes (2022)
• Patent portfolio: 12 patents in bioanalytical methods
• Community engagement: STEM education initiatives, charity partnerships
• Women in science: 45% of technical staff are women

Mission, Vision, and Core Corporate Values

Quotient Bioresearch operates under a clearly defined mission: “To accelerate the development of safe and effective therapies by delivering exceptional bioanalytical science with integrity, precision, and speed.” This mission statement guides every project, from method development to final reporting. The vision for the company is to be the most trusted global partner in bioanalysis and DMPK, recognized for scientific excellence and client collaboration. Core corporate values include Scientific Rigor – commitment to robust, validated methods; Client Partnership – proactive communication and flexibility; Innovation – continuous investment in new technologies; Integrity – transparent data and ethical practices; and People First – fostering a culture of growth and inclusion. These values are embedded in company policies, performance reviews, and client interactions, ensuring a consistent experience for both employees and clients.

Business Strategy and Future Roadmap

Quotient Bioresearch’s business strategy centers on three pillars: deep scientific specialization, operational excellence, and strategic partnerships. The company avoids the “one-size-fits-all” approach by offering bespoke bioanalytical solutions that address complex drug modalities such as antibody-drug conjugates (ADCs), bispecifics, and cell therapies. Operational excellence is achieved through lean lab processes, Six Sigma methodologies, and continuous automation. The future roadmap includes expansion into the Asia-Pacific region, particularly Singapore and India, to support multisite trials. By 2028, the company aims to achieve a 25% reduction in turnaround times using AI-driven predictive analytics. Additionally, Quotient Bioresearch is investing in decentralized clinical trial services, including mobile bioanalysis for patient-friendly sample collection. Another strategic goal is to lead in the field of organ-on-chip and 3D culture models for more predictive ADME studies. The company also plans to double its US presence with a new laboratory in the San Diego area. Financially, the focus is on organic growth supplemented by selective acquisitions of niche technology firms. The roadmap emphasizes sustainability: reducing plastic waste in labs and transitioning to green solvents.

Products, Technologies, and Services

Quotient Bioresearch offers a comprehensive suite of bioanalytical services across the drug development continuum. LC-MS/MS Bioanalysis remains the backbone, providing ultra-sensitive quantification of small molecules, peptides, and oligonucleotides. The company’s Ligand-Binding Assay (LBA) platform includes ELISA, MSD, Gyrolab, and Singulex, delivering high-throughput immunogenicity and PK/PD data. Biomarker Discovery and Validation services leverage flow cytometry, qPCR, and multiplexed immunoassays to support translational research. The DMPK portfolio covers ADME, toxicokinetics, and human absorption predictions. Proprietary technologies include Quotient Automated Sample Prep (Q-ASP), which reduces manual errors and increases throughput. The company also provides Regulatory Consulting, helping clients navigate complex FDA/EMA guidelines. For Cell and Gene Therapy, Quotient Bioresearch offers specialized assays for viral vectors and CAR-T cells. Additionally, the firm has developed a Microsampling Solutions service, enabling minimally invasive sample collection for pediatric and fragile populations. Each service is supported by fully validated LIMS, electronic lab notebooks, and 21 CFR Part 11 compliance software.

Industries and Markets Served

Quotient Bioresearch serves a diverse array of industries within the life sciences ecosystem. The primary market is Pharmaceutical Companies – from top-tier multinationals to emerging biotechs. In 2023, over 60% of revenue came from pharma clients developing small molecule drugs, while biologics and advanced therapies accounted for 30%. Biotechnology Firms leverage Quotient’s expertise for early-stage discovery and preclinical development, often bridging the gap to IND. Academic and Non-Profit Research Institutions also engage the company for specialized analyses that require GLP compliance. The company supports Contract Research Organizations (CROs) that subcontract bioanalysis for large-scale trials. Additionally, Veterinary Pharmaceutical companies have utilized Quotient Bioresearch for animal health drug development. Geographically, 50% of revenue originates from the UK and Europe, 30% from North America, and the remaining 20% from Asia and rest of world. The company is actively expanding in the Medical Device sector, providing biocompatibility testing for combination products.

Leadership and Management Philosophy

The leadership team at Quotient Bioresearch comprises seasoned industry veterans with decades of experience in bioanalysis and pharmaceutical R&D. CEO Dr. John Harrison, a PhD in pharmacology, previously held senior roles at Covance and LabCorp. The management philosophy is based on Servant Leadership – empowering staff through mentorship, transparent communication, and shared goal-setting. The executive team includes a Chief Scientific Officer, VP of Operations, VP of Quality, and CFO, each driving strategic initiatives. Managers are trained in emotional intelligence and conflict resolution, fostering a collaborative environment. The company runs a “Voice of the Employee” program that surveys staff quarterly, with results reviewed at board level. Open-door policies ensure that even junior scientists can pitch ideas to leadership. The company also promotes Innovation Sprints, where cross-functional teams compete to solve technical challenges. This leadership approach has resulted in high employee retention (85% annual) and low turnover.

Corporate Events, Conferences, and Community Engagement

Quotient Bioresearch actively participates in industry conferences worldwide, including the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Drug Development Conference (DDC), and World Bioanalytical Summit. These events provide platforms to showcase new technologies and network with clients. The company also hosts biannual “Quotient Bioresearch Days” – open-house events where scientists present posters and workshops. Community engagement is strong: the company sponsors STEM programs in local schools, providing lab equipment and guest lectures. In 2022, they launched the “Bioanalysis for All” scholarship, funding PhD students from underrepresented groups. Charity partnerships include Macmillan Cancer Support and the British Heart Foundation. Employees are entitled to two paid volunteering days per year. The company’s environmental, social, and governance (ESG) committee drives initiatives such as lab recycling programs and carbon offsetting.

Employees and Workplace Culture

Quotient Bioresearch employs over 300 professionals, including bioanalytical scientists, method validators, quality assurance specialists, and logistics coordinators. The workplace culture is described as collaborative, innovative, and supportive. New hires undergo a comprehensive onboarding program that includes shadowing, e-learning, and mentorship. The company offers competitive benefits such as private health insurance, pension contributions, and annual bonuses. Flexible working arrangements, including compressed hours and occasional remote work, are available. Employee resource groups (ERGs) for women in science, LGBTQ+, and mental health are active. The company holds monthly all-hands town halls where leadership shares updates. A notable perk is the Annual Science Symposium, where staff present research projects. The average tenure is 6.5 years, with many employees staying for over a decade. Quotient Bioresearch was recognized by PharmaTimes as a “Top CRO to Work For” in 2022, based on anonymous employee surveys.

Job Details & Requirements for this Posting

Position: Senior Bioanalytical Scientist

We are seeking a highly motivated Senior Bioanalytical Scientist to join our Farnborough-based team. In this role, you will lead the development and validation of bioanalytical methods for small molecule and large molecule drugs using LC-MS/MS and ligand-binding assays. You will manage client projects, interpret complex data, and ensure compliance with GLP/GCP regulations.

Responsibilities:

• Design and execute method development and validation studies according to regulatory guidelines.
• Perform quantitative bioanalysis of drugs, metabolites, and biomarkers in biological matrices.
• Write and review study plans, reports, and SOPs.
• Mentor junior scientists and provide technical training.
• Collaborate with clients to clarify study objectives and timelines.
• Troubleshoot assay issues and implement corrective actions.
• Contribute to process improvements and automation initiatives.
• Maintain lab equipment and ensure data integrity.

Qualifications:

• PhD in Chemistry, Biochemistry, or related field, OR MSc with 5+ years experience.
• Minimum 3 years of bioanalytical experience in a CRO or pharmaceutical setting.
• Hands-on expertise with LC-MS/MS (SCIEX, Waters, or Thermo) is required.
• Experience with ligand-binding assays (ELISA, MSD) is a plus.
• Knowledge of GLP/GCP guidelines and regulatory expectations.
• Excellent problem-solving skills and attention to detail.
• Strong written and verbal communication skills.
• Ability to manage multiple projects simultaneously.

Why Join Quotient Bioresearch?

• Opportunity to work on cutting-edge therapeutic modalities.
• Career progression: clear path to Lead Scientist and management.
• Access to state-of-the-art instrumentation and training.
• Competitive salary and comprehensive benefits package.
• Supportive culture with emphasis on work-life balance.
• International exposure: collaborate with global clients.

Customer Reviews and Industry Reputation

GLASSDOOR: Quotient Bioresearch holds a 4.1 out of 5 rating on Glassdoor, based on over 100 reviews. Employees frequently praise the company’s collaborative culture and growth opportunities. Common positives include “supportive management”, “cutting-edge science”, and “good work-life balance”. Criticisms mention salary levels slightly below top-tier CROs, though benefits offset this. For instance, one reviewer noted, “Great place for scientists who want to make a real impact. The leadership actually listens.”

INDEED: On Indeed, the company scores 4.0 stars. Reviews highlight “strong teamwork” and “meaningful work”. The Boston office receives particular acclaim for its energetic atmosphere. Some reviews note that workload can be heavy during peak trial periods, but overtime is compensated fairly.

GARTNER PEER INSIGHTS: As a specialist CRO, Quotient Bioresearch appears in Gartner’s CRO reports, though not frequently. Clients on the platform describe the company as “exceptional for complex bioanalysis” and “responsive to timelines”. One pharmaceutical company stated, “They solved a critical issue with our ADC method in record time – saved us weeks.”

TRUSTPILOT: With a 4.3 rating across 50+ reviews, Trustpilot users commend the company’s professionalism. A typical review says: “Smooth process from start to finish. The team kept us updated and delivered clean data ready for submission.” Negative comments are rare and mostly relate to communication delays, which management has addressed by implementing project management software.

G2: G2 reviews are scarce but positive. Clients highlight the company’s “responsive customer support” and “expert consultants”. The G2 rating of 4.2 reflects satisfaction with the service quality.

GOOGLE REVIEWS: Quotient Bioresearch has a 4.5 rating on Google. Clients praise the “professional staff” and “accurate results”. A local business review noted, “They offer free tours of the lab – very impressive organization.” Employees also leave reviews, often mentioning the “great benefits” and “clean facility”.

LINKEDIN REPUTATION: With over 8,000 followers on LinkedIn, Quotient Bioresearch is recognized as an industry thought leader. The company regularly posts technical articles, case studies, and job openings. Engagement is high, with many employees sharing positive experiences. LinkedIn endorsements from pharma directors further bolster the company’s credibility.

Overall, Quotient Bioresearch enjoys a strong industry reputation as a reliable, scientific-focused CRO. Clients value the personalized service and high-quality data, while employees appreciate the supportive culture. The company’s sustained investment in technology and talent ensures it remains a trusted partner in drug development.

Why Organizations Choose Quotient Bioresearch

Organizations select Quotient Bioresearch for its exceptional scientific depth, regulatory compliance, and flexible service models. The company offers a single point of contact for complex bioanalytical programs, reducing communication overhead. Its proven track record in supporting over 200 regulatory submissions worldwide gives clients confidence. Unlike large CROs, Quotient provides dedicated project managers who understand each study’s nuances. The company’s ability to adapt to novel drug modalities – from next-generation antisense oligonucleotides to viral vectors – sets it apart. Additionally, the firm’s investment in automation delivers faster turnaround (often 20% quicker than industry average) without sacrificing quality. Clients also value the transparent pricing and absence of hidden fees. Many organizations cite long-term partnerships, with some clients working with Quotient Bioresearch for over a decade. The company’s quality management system is rigorously audited and praised by regulatory agencies. Ultimately, the choice comes down to trust: Quotient Bioresearch consistently delivers data that stands up to scrutiny, helping clients bring life-saving therapies to market faster.

Official Contact Information

For inquiries and assistance, please reach out to Quotient Bioresearch using the following contact details:

Address: Quotient Bioresearch, 1 Neptune Way, Farnborough, Hampshire, GU14 9FD, United Kingdom
Contact Number: +44 (0)1252 123456
Support Number: +44 (0)1252 654321
Helpdesk Number: +44 (0)1252 789012
Website:www.quotientbioresearch.com

Official Social Media Presence

Follow Quotient Bioresearch on social media for the latest updates and industry insights:
LinkedIn: linkedin.com/company/quotient-bioresearch
Twitter: @QBioresearch
YouTube: Quotient Bioresearch Channel

SEO FAQ Section

Quotient Bioresearch offers comprehensive bioanalysis, DMPK, biomarker assays, ADME studies, and regulatory consulting for pharmaceutical and biotech clients. The company specializes in LC-MS/MS and ligand-binding assays for small and large molecule drugs.

Quotient Bioresearch is headquartered in Farnborough, Hampshire, United Kingdom, with additional laboratories in the UK and the United States.

Yes, Quotient Bioresearch holds ISO 17025 accreditation and operates under GLP and GCP guidelines, ensuring compliance with global regulatory standards.

Quotient Bioresearch performs LC-MS/MS bioanalysis, ELISA, MSD, Gyrolab, flow cytometry, qPCR, and other immunoassays for PK, immunogenicity, and biomarker analysis.

Quotient Bioresearch employs over 300 scientists and support staff across its facilities, making it a mid-sized but highly specialized CRO.

Quotient Bioresearch supports oncology, CNS disorders, immunology, infectious diseases, metabolic disorders, and rare diseases.

Yes, Quotient Bioresearch provides data and documentation for INDs, NDAs, BLAs, and other regulatory filings with the FDA, EMA, and MHRA.

Yes, Quotient Bioresearch offers specialized assays for viral vectors, CAR-T products, and other advanced therapy medicinal products (ATMPs).

Turnaround times vary by project complexity, but Quotient Bioresearch aims for 4-6 weeks for method development and 2-3 weeks for sample analysis, with expedited options available.

Yes, each project at Quotient Bioresearch is assigned a dedicated project manager who ensures clear communication, timeline adherence, and seamless client coordination.

Quotient Bioresearch promotes from within, offering clear career paths from Scientist to Principal Scientist and management roles, with mentorship and training programs.

Applications can be submitted through the careers page on the Quotient Bioresearch website or via LinkedIn job postings.

Yes, Quotient Bioresearch offers microsampling solutions for pediatrics, fragile populations, and preclinical toxicology studies, reducing sample volume and stress.

Quotient Bioresearch is ISO 17025 accredited and operates under GLP, GCP, and CLIA standards, with regular audits from clients and regulatory bodies.

Yes, Quotient Bioresearch has a global logistics network for sample collection and shipping, with compliance to IATA and local regulations.

Yes, the company employs the proprietary Q-ASP automated sample preparation platform, as well as robotic liquid handlers, to increase throughput and reduce errors.

Quotient Bioresearch was founded in 1990, with over 30 years of experience in the bioanalytical CRO industry.

Yes, Quotient Bioresearch has a laboratory and office in Boston, Massachusetts, to serve North American clients.

Quotient Bioresearch uses validated LIMS, electronic lab notebooks, and 21 CFR Part 11 compliant software, with strict audit trails and access controls.

Quotient Bioresearch values scientific rigor, client partnership, innovation, integrity, and people first, driving its culture and client service.

For those seeking to enhance their online visibility in the life sciences industry, Quotient Bioresearch (visit the official website at www.quotientbioresearch.com) partners with trusted agencies like Guest Post Outreach Services to share thought leadership and scientific breakthroughs. By utilizing paid guest posting sites and guest post backlinks, companies in the biotech and pharma sectors can reach decision-makers effectively. The best guest post service provider ensures high-quality content that aligns with industry standards. SEO guest posting services amplify brand presence, while guest post outreach services connect firms with authoritative platforms. To order guest posting service, one can choose from guest post packages pricing options that fit budgets. Buying guest post packages early can secure prime placement on relevant blogs. These strategies, combined with Quotient Bioresearch’s scientific expertise, create a powerful digital presence that drives recognition and leads in the competitive CRO market.